Lincoln has over 25 years of experience in healthcare as a surgeon, executive and investor. Prior to joining Vertex, Lincoln served as CEO and Board Member of Quality Healthcare, Hong Kong’s first publicly listed healthcare company. He led the growth and eventual buyout by Fortis Group in 2010. In 2009, Lincoln was selected as Outstanding Entrepreneur of HK. He also held committee positions with Hong Kong Government Food and Health Bureau on e-health Records and Primary Care Delivery Models and an advisory member of Hong Kong Trade and Development Council. Since 2013, Lincoln has been an operating partner advisor for Advent International in healthcare. He has also held an ENT Consultant position at Singapore General Hospital.
Lincoln is currently on the Board of Holaira, Visterra and Sensimed. Notable past investments include Twelve (acquired by Medtronic), Arana Therapeutics (acquired by Cephalon), Biosensors International (IPO) and Phoenix Hospital Group (IPO).
Lincoln holds a MBBS from the National University of Singapore. He is a Fellow of the Royal College of Surgeons Edinburgh and a Fellow Academy of Medicine Singapore in Otorhinolaryngology Head & Neck Surgery.
Chris has over 15 years of healthcare investing experience. Prior to joining Vertex, Chris led numerous medtech and biopharma investments at New Enterprise Associates and Essex Woodlands. He worked with seven companies that have since gone public or been successfully acquired, worth over US$1.5 billion in value. Chris is also a Consulting Associate Professor of Medicine at Stanford. He has twelve patents issued and several pending in the fields of interventional neuroradiology and interventional cardiology. Previously, Chris worked in operating roles at Guidant and Pfizer.
Chris is currently on the board of Moximed, Ivantis and Kona Medical. Notable past investments include Twelve (acquired by Medtronic), Entellus Medical (IPO), Nellix Endovascular (acquired by ELGX), Bridgepoint Medical (acquired by BSC), Evalve (acquired by Abbott) and Glycomimetics (IPO).
Chris holds an MD, MBA, MS in Biomechanical Engineering and BS in Biological Science from Stanford University.
Carolyn Ng is the Investment Director of Vertex Ventures HC and is based in the Singapore office. Prior to joining Vertex, Carolyn was a Consultant at Deallus Consulting, a specialized life sciences strategy consulting firm. While at Deallus, she led multiple consulting projects for large pharmaceutical companies supporting due diligence of in-/out-licensing opportunities, analyzing competitive landscapes of emerging classes of therapeutics, and formulating go-to-market strategies for Asian markets. Carolyn was also a molecular oncology research scientist in YLL School of Medicine, the National University of Singapore. She was a recipient of the NUS Graduate School for Integrative Sciences and Engineering PhD scholarship, and holds the patent of a novel small molecule nuclear receptor activator indicated for the treatment of neuroblastoma.
Carolyn holds a PhD in Cancer Molecular Biology from the NUS Graduate School for Integrative Sciences and Technology, and also holds a BS (Pharmacy) (Honours) degree from the National University of Singapore.
Lori Hu joined the Vertex Ventures HC Palo Alto office in 2015 focusing on global healthcare investments. Prior to Vertex, Lori was an Associate Director for Business Development at Bristol-Myers Squibb, identifying and executing licensing, partnerships and transactions for the Chinese market. She has also worked with SR One, the corporate venture capital arm of GlaxoSmithKline in Boston. Previously, she was a strategy consultant in the health & life sciences practice at Accenture based across Singapore, China and South Africa.
Lori graduated with an MBA from The Wharton School, and MA in International Studies from the University of Pennsylvania where she was a Leonard Lauder Fellow. She also holds a BSE in Biomedical Engineering from Duke University.